Fortress Biotech to Participate in Three September 2020 Virtual Investor Conferences

NEXT STORY
Genmab Announces that Janssen has Submitted a Supplemental Biologics License Application to U.S. FDA for use of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) in Patients with Light-chain (AL) Amyloidosis
PREV STORY
Immunoscore® to select patients in the POCHI trial, a phase II multicenter trial testing immunotherapy with chemotherapy and bevacizumab in metastatic colorectal cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Shire plc : Director Declaration

Director Declaration May 22, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") ...

author_avatar
NASDAQ Market News

Konferensi Pers Konferensi Kanker Paru-Paru Dunia Hari Senin: Hasil Riset Klinis dan Perbedaan Gender pada Kelangsungan Hidup Penderita Kanker Paru-Paru

TORONTO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Pada konferensi pers hari ini di Konferensi ...

author_avatar
NASDAQ Market News

FIT Biotech Oy: Conversion of FIT Biotech Oy’s Convertible Capital Notes into shares

FIT Biotech Oy Company release February 22, 2018 at 3:00 PM EET Conversion of ...

author_avatar
NASDAQ Market News